Search Results - "mAbs"

Antibodies to watch in 2022 by Kaplon, Hélène, Chenoweth, Alicia, Crescioli, Silvia, Reichert, Janice M.

“…In this 13th annual installment of the annual 'Antibodies to Watch' article series, we discuss key events in commercial antibody therapeutics development that…”
Get full text

Antibodies to watch in 2023 by Kaplon, Hélène, Crescioli, Silvia, Chenoweth, Alicia, Visweswaraiah, Jyothsna, Reichert, Janice M.

“…In this 14th installment of the annual Antibodies to Watch article series, we discuss key events in commercial monoclonal antibody therapeutics development…”
Get full text

Antibodies to watch in 2020 by Kaplon, Hélène, Muralidharan, Mrinalini, Schneider, Zita, Reichert, Janice M.

“…This 2020 installment of the annual 'Antibodies to Watch' series documents the antibody therapeutics approved in 2019 and in regulatory review in the United…”
Get full text

Antibodies to watch in 2019 by Kaplon, Hélène, Reichert, Janice M.

“…For the past 10 years, the annual 'Antibodies to watch' articles have provided updates on key events in the late-stage development of antibody therapeutics,…”
Get full text

Antibodies to watch in 2021 by Kaplon, Hélène, Reichert, Janice M.

“…In this 12 th annual installment of the Antibodies to Watch article series, we discuss key events in antibody therapeutics development that occurred in 2020…”
Get full text

The making of bispecific antibodies by Brinkmann, Ulrich, Kontermann, Roland E.

“…During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The 'zoo' of bispecific antibodies is…”
Get full text

The therapeutic monoclonal antibody market by Ecker, Dawn M, Jones, Susan Dana, Levine, Howard L

“…Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so…”
Get full text

Structure, heterogeneity and developability assessment of therapeutic antibodies by Xu, Yingda, Wang, Dongdong, Mason, Bruce, Rossomando, Tony, Li, Ning, Liu, Dingjiang, Cheung, Jason K, Xu, Wei, Raghava, Smita, Katiyar, Amit, Nowak, Christine, Xiang, Tao, Dong, Diane D., Sun, Joanne, Beck, Alain, Liu, Hongcheng

“…Increasing attention has been paid to developability assessment with the understanding that thorough evaluation of monoclonal antibody lead candidates at an…”
Get full text

Antibodies to watch in 2018 by Kaplon, Hélène, Reichert, Janice M.

“…The pace of antibody therapeutics development accelerated in 2017, and this faster pace is projected to continue through 2018. Notably, the annual number of…”
Get full text

The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity by Pereira, Natasha A., Chan, Kah Fai, Lin, Pao Chun, Song, Zhiwei

“…Therapeutic monoclonal antibodies are the fastest growing class of biological therapeutics for the treatment of various cancers and inflammatory disorders. In…”
Get full text

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates by Donaghy, Heather

“…Antibody-drug conjugates (ADCs) represent a new class of cancer therapeutics. Their design involves a tumor-specific antibody, a linker and a cytotoxic…”
Get full text

Predicting Antibody Developability Profiles Through Early Stage Discovery Screening by Bailly, Marc, Mieczkowski, Carl, Juan, Veronica, Metwally, Essam, Tomazela, Daniela, Baker, Jeanne, Uchida, Makiko, Kofman, Ester, Raoufi, Fahimeh, Motlagh, Soha, Yu, Yao, Park, Jihea, Raghava, Smita, Welsh, John, Rauscher, Michael, Raghunathan, Gopalan, Hsieh, Mark, Chen, Yi-Ling, Nguyen, Hang Thu, Nguyen, Nhung, Cipriano, Dan, Fayadat-Dilman, Laurence

“…Monoclonal antibodies play an increasingly important role for the development of new drugs across multiple therapy areas. The term 'developability' encompasses…”
Get full text

Targeting cancer with antibody-drug conjugates: Promises and challenges by Dean, Alexis Q., Luo, Shen, Twomey, Julianne D., Zhang, Baolin

“…Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that utilize antibodies to selectively deliver cytotoxic drugs to the tumor…”
Get full text

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma by Overdijk, Marije B, Verploegen, Sandra, Bögels, Marijn, van Egmond, Marjolein, van Bueren, Jeroen J Lammerts, Mutis, Tuna, Groen, Richard WJ, Breij, Esther, Martens, Anton CM, Bleeker, Wim K, Parren, Paul WHI

“…Daratumumab (DARA) is a human CD38-specific IgG1 antibody that is in clinical development for the treatment of multiple myeloma (MM). The potential for IgG1…”
Get full text

Phage display-derived human antibodies in clinical development and therapy by Frenzel, André, Schirrmann, Thomas, Hust, Michael

“…Over the last 3 decades, monoclonal antibodies have become the most important class of therapeutic biologicals on the market. Development of therapeutic…”
Get full text

Antibodies to watch in 2017 by Reichert, Janice M.

“…Over 50 investigational monoclonal antibody (mAb) therapeutics are currently undergoing evaluation in late-stage clinical studies, which is expected to drive a…”
Get full text

Site-specific antibody drug conjugates for cancer therapy by Panowski, Siler, Bhakta, Sunil, Raab, Helga, Polakis, Paul, Junutula, Jagath R

“…Antibody therapeutics have revolutionized the treatment of cancer over the past two decades. Antibodies that specifically bind tumor surface antigens can be…”
Get full text

Forced degradation of recombinant monoclonal antibodies: A practical guide by Nowak, Christine, K. Cheung, Jason, M. Dellatore, Shara, Katiyar, Amit, Bhat, Ram, Sun, Joanne, Ponniah, Gomathinayagam, Neill, Alyssa, Mason, Bruce, Beck, Alain, Liu, Hongcheng

“…Forced degradation studies have become integral to the development of recombinant monoclonal antibody therapeutics by serving a variety of objectives from…”
Get full text

Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline by Tuccori, Marco, Ferraro, Sara, Convertino, Irma, Cappello, Emiliano, Valdiserra, Giulia, Blandizzi, Corrado, Maggi, Fabrizio, Focosi, Daniele

“…Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In…”
Get full text

Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms by Wada, Ryuta, Matsui, Makoto, Kawasaki, Nana

“…Glycosylation of the conserved asparagine residue in each heavy chain of IgG in the CH2 domain is known as N-glycosylation. It is one of the most common…”
Get full text